An observational study in Myeloid Diseases, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 16 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Austrian Myeloid Registry (aMYELOIDr) is a non-interventional study. It collects data from patients with the myeloid diseases, primarily myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).The aMYELOIDr is multi-center database collecting data at various sites in Austria and potentially also at other centers in other countries in future. The registry has an electronic case report form (eCRF), where all data is entered by clinical trial personnel and/or physicians. It is set up to collect real-world experience in the management of patients with these diseases in Austria.
Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with AML, MDS, CMML or PMF according to WHO 2016 diagnostic criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with WHO 2016 diagnosis of AML
Other: Non-interventional
Patients with WHO 2016 diagnosis of MDS
Other: Non-interventional
Patients with WHO 2016 diagnosis of CMML
Other: Non-interventional
Patients with WHO 2016 diagnosis of PMF
Other: Non-interventional
Only routine clinical data, which has already been recorded in the patient's medical chart, will be documented. Any other data assessments (e.g. quality of life analyses such as EQ-5D and QLQ-C30 have been approved by the Ehtikkommission für das Bundesland Salzburg and are optional.
To assess the treatment patterns (therapeutic landscape) of patients with myeloid diseases.
Due to the non-interventional nature of the aMYELOIDr, treatment indication, the decision to offer treatment, treatment choice, dose, schedule and dose reductions/escalations shall be exclusively based on the risk/benefit estimation of the treating physician. We recommend compliance current guidelines.
Time frame: Through study completion, median expected within 100 months
Impact of front-line treatment on overall survival (OS)
Time frame: Through study completion, median expected within 100 months
Impact of number and choice of treatment lines on OS as of initial diagnosis and/or as of treatment start
Time frame: Through study completion, median expected within 100 months
Overall response rate (ORR)
Response will be assessed according to current guidelines for the respective disease. Due to the non-interventional nature of the aMYELOIDr, timepoints and types of response assessment shall be exclusively based on the risk/benefit estimation of the treating physician. We recommend compliance current guidelines.
Time frame: Through study completion, median expected within 100 months
Event free survival (EFS)
Events include treatment failure, progressive disease, relapse after CR/CRi, death from any cause. Patients lost to-follow-up or still alive ans without event will be censored at last follow-up date
Time frame: Through study completion, median expected within 100 months
AML transformation
Time to transformation to AML for patients with a non-AML initial diagnosis
Time frame: Through study completion, median expected within 100 months
Treatment safety
Investigators should report adverse reactions (for which a causal role of a medicine is suspected) to the concerned competent authorities following regulations in the current or future versions of Austrian legislation (Pharmakovigilanz-Verordnung 2013 (PhVO, Regulation on Pharmacovigilance), Österreichisches Arzneimittel Gesetz (AMG, Austrian Medicinal Products Act). Participation in this registry does not exempt the participating center from their legal reporting obligations. Documentation of causality, duration, frequency and severity of adverse events (AEs) according to Common Terminology Criteria for AE (CTCAE v.5).
Time frame: Through study completion, median expected within 100 months
Concomitant treatments
Concomitant treatments (number of administration of e.g. prophylactic antibiotics, antivirals, antifungals)
Time frame: Through study completion, median expected within 100 months
Treatment characteristics
Among others, the following treatment characteristics will be assessed for each treatment line: substance
Time frame: Through study completion, median expected within 100 months
Treatment characteristics
Among others, the following treatment characteristics will be assessed for each treatment line: application date
Time frame: Through study completion, median expected within 100 months
Treatment characteristics
Among others, the following treatment characteristics will be assessed for each treatment line: route
Time frame: Through study completion, median expected within 100 months
Treatment characteristics
Among others, the following treatment characteristics will be assessed for each treatment line: dose
Time frame: Through study completion, median expected within 100 months
Treatment characteristics
Among others, the following treatment characteristics will be assessed for each treatment line: inpatient or outpatient setting
Time frame: Through study completion, median expected within 100 months
Concomitant treatments best supportive care (BSC)
Concomitant best supportive care (BSC) measures (e.g. number of transfusions, growth factors, iron chelators)
Time frame: Through study completion, median expected within 100 months
Quality of life assessment EQ-5D-5L (optional)
EuroQol-5 Dimensions with 5 Levels. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
Time frame: Through study completion, median expected within 100 months
EORTC Quality of life assessment QLQ-C30 (optional)
European Organisation for Research and Treatment of Cancer Quality of life 30-item questionnaire of cancer patients incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation anddiarrhoea) and perceived financial impact of the disease. It has four-point scale which are coded with "Not at all", "A little", "Quite a bit" and "Very much"
Time frame: Through study completion, median expected within 100 months
Minimal residual disease
Assess how many and which patients in Austria have minimal residual disease (MRD) assessments, assessed by which techniques and at which timepoints.
Time frame: Through study completion, median expected within 100 months
MRD-negativity on OS
Assess the impact of MRD-negativity on OS. MRD assessment via flow-cytometry and polymerase chain reactions according to the current ELN guidelines 2017 shall be exclusively based on the risk/benefit estimation of the treating physician.
Time frame: Through study completion, median expected within 100 months
Prognostic and predictive markers
Analyses of various factors known or thought to influence OS, ORR, EFS, PFS and time to next treatment in order to validate existing or establish novel prognostic and predictive markers
Time frame: Through study completion, median expected within 100 months
Plan to share: Undecided
Started Jul 2020 (actual). Primary completion is estimated for Apr 2029, 105 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arbeitsgemeinschaft medikamentoese Tumortherapie